N/A N=411 Randomized Double-blind Diagnostic

Robotic Versus Electromagnetic Bronchoscopy for Pulmonary LesIon AssessmeNT: (the RELIANT Trial)

Peripheral Pulmonary Lesions

Bottom Line

View on ClinicalTrials.gov: NCT05705544 ↗

Enrolled (actual)

411

Serious AEs

2.9%

Results posted

Apr 2025

Primary outcome: Primary: Diagnostic Yield — 157; 158 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: ILLUMISITE™ Platform (EMN bronchoscopy) (Device); Ion™ Endoluminal System (SSCB bronchoscopy) (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Vanderbilt University Medical Center
Primary completion: Apr 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Diagnostic Yield	157; 158	—
SECONDARY Duration of Procedure	32.0; 37.0	—

Summary

This is an investigator-initiated, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the Ion™ Endoluminal System (SSCB) to the ILLUMISITE™ Platform (EMN bronchoscopy) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.

Eligibility Criteria

Inclusion Criteria

18 years of age or older at time of bronchoscopy.

Scheduled for navigational bronchoscopy for the evaluation of a peripheral pulmonary lesion.

Exclusion Criteria

Enrolled in a different study requiring use of one of these specific platforms (i.e., ILLUMISITE™ Platform (EMN) or Ion™ Endoluminal System (SSCB)).

Subject declines to participate.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05705544). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.